SCHEMBL18174563

SCHEMBL18174563

Cc1c(-c2ccncc2)cccc1-c1c2ccccc2c(-c2cccc(-c3ccncc3)c2C)c2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 3/20 0.45
MAPK1 P28482 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPK14 Q16539 2/20 0.42
CYP17A1 P05093 1/20 0.42
CYP1A2 P05177 1/20 0.42
PIK3CD O00329 1/20 0.42
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
MAPK11 Q15759 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
NOTUM Q6P988 1/20 0.40
RECQL P46063 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18174579 0.87 PIK3CA (0.49) IMPDH2MAPK14CYP17A1CYP1A2PDCD1
SCHEMBL10032891 0.85 MAPK9 (0.46) MAPK1HSD17B10MAPK14CYP17A1MAPK11
SCHEMBL21742828 0.84 NOTUM (0.58) MAPK14CYP17A1CYP1A2PIK3CDPDCD1
SCHEMBL18174560 0.81 CYP11B1 (0.50) CYP17A1CYP1A2PDCD1CD274KDM4E
SCHEMBL13979054 0.80 NOTUM (0.46) IMPDH2MAPK1HSD17B10MAPK14CYP1A2
SCHEMBL10032918 0.78 MAPK14 (0.41) MAPK14CYP17A1CYP1A2MAPK11
SCHEMBL16512261 0.78 IMPDH2 (0.50) IMPDH2MAPK1HSD17B10MAPK14PIK3CD
SCHEMBL26259561 0.77 PIK3CD (0.61) IMPDH2MAPK1HSD17B10MAPK14CYP17A1
SCHEMBL10017212 0.77 IMPDH2 (0.42) IMPDH2MAPK1HSD17B10MAPK14CYP17A1
SCHEMBL26259581 0.76 PIK3CD (0.45) IMPDH2MAPK1HSD17B10MAPK14CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9478750-B2 Anthracene derivative and organic electroluminescent element using the same JNC CORPORATION (JP) 2016-10-25 US disclosed
US-9478750-B2 Anthracene derivative and organic electroluminescent element using the same JNC CORPORATION (JP) 2016-10-25 US disclosed
US-20150203469-A1 ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF CELGENE CORPORATION 2015-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203469-A1 ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF AQP3, CYP2D6, CYP3A5 IMPDH2 167/4885MAPK1 3763/4885HSD17B10 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.